The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Open accessAbstract
CONTEXT: In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. OBJECTIVE: To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. DESIGN, SETTING, AND PARTICIPANTS: A total of 16,608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12,788 (83%) of the surviving participants. MAIN OUTCOME MEASURES: Invasive breast cancer incidence and breast cancer mortality. RESULTS: In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46; P = .004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs 43 [16.2%], respectively; HR, 1.78; 95% CI, 1.23-2.58; P = .03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96; 95% CI, 1.00-4.04; P = .049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P = .045) among women who received estrogen plus progestin compared with women in the placebo group. CONCLUSIONS: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000611.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Self-citationPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
Self-citationNational Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence
Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004) · JAMA · doi:10.1001/jama.291.1.47 · Cited by 983
Self-citationThe Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 982
Self-citationImplementation of the women's health initiative study design
Anderson, G. L., Manson, J., Wallace, R., Lund, B., Hall, D., Davis, S., Shumaker, S., Wang, C.-Y., Stein, E., & Prentice, R. L. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00043-7 · Cited by 756
Self-citationThe women's health initiative recruitment methods and results
Hays, J., Hunt, J. R., Hubbell, F. A., Anderson, G. L., Limacher, M., Allen, C., & Rossouw, J. E. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00042-5 · Cited by 742
Self-citationOutcomes ascertainment and adjudication methods in the women's health initiative
Curb, J. D., Mctiernan, A., Heckbert, S. R., Kooperberg, C., Stanford, J., Nevitt, M., Johnson, K. C., Proulx-Burns, L., Pastore, L., Criqui, M., et al. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00048-6 · Cited by 698
Self-citationPinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472
Self-citationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss, G. (2008) · JAMA · doi:10.1001/jama.299.9.1036 · Cited by 396
Estrogen and Angiogenesis: A Review
Losordo, D. W., & Isner, J. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.6 · Cited by 352
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., Rodabough, R. J., Chien, J. W., Wactawski-Wende, J., Gass, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61526-9 · Cited by 322
Self-citationShen, Y., Yang, Y., Inoue, L. Y. T., Munsell, M. F., Miller, A. B., & Berry, D. A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji239 · Cited by 249
Anderson, G. L., Chlebowski, R. T., Rossouw, J. E., Rodabough, R. J., McTiernan, A., Margolis, K. L., Aggerwal, A., Curb, J. D., Hendrix, S. L., Hubbell, F. A., et al. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.004 · Cited by 239
Self-citationBreast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Day, S., & Bevers, T. B. (2011) · Breast Diseases: A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.032 · Cited by 187
Clarke, C. A., Glaser, S. L., Uratsu, C. S., Selby, J. V., Kushi, L. H., & Herrinton, L. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6504 · Cited by 160
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder, S. M., Murthy, L. J., & Stancel, G. M. (1998) · PubMed · Cited by 156
Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women
Prentice, R. L., Chlebowski, R. T., Stefanick, M. L., Manson, J. E., Pettinger, M. B., Hendrix, S. L., Hubbell, F. A., Kooperberg, C. L., Kuller, L. H., Lane, D. S., et al. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn044 · Cited by 154
Self-citationFournier, A., Mesrine, S., Boutron‐Ruault, M., & Clavel‐Chapelon, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6432 · Cited by 151
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
Holli, K. A., Isola, J., & Cuzick, J. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3115 · Cited by 142
Chen, W. Y., Hankinson, S. E., Schnitt, S. J., ROSNER, B. A., Holmes, M. D., & Colditz, G. A. (2004) · Cancer · doi:10.1002/cncr.20499 · Cited by 133
Kerlikowske, K. M., Miglioretti, D. L., Ballard-Barbash, R. R., Weaver, D. L., Buist, D. S. M., Barlow, W. E., Cutter, G., Geller, B. M., Yankaskas, B. C., Taplin, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.151 · Cited by 129
Toh, S., Hernández–Díaz, S., Logan, R. W., Rossouw, J. E., & Hernán, M. Á. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-4-201002160-00005 · Cited by 123
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Sihto, H. J., Lundin, J. E., Lehtimäki, T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5003 · Cited by 113
Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy
Chlebowski, R. T. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.123 · Cited by 107
Self-citationLiang, Y., Besch-Williford, C. L., Brekken, R. A., & Hyder, S. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1103 · Cited by 88
Calvo, A., Catena, R., Noble, M. S., Carbott, D., Bazo, I. G., González-Moreno, Ó., Huh, J.-I., Sharp, R., Qiu, T.-H., Anver, M. R., et al. (2008) · Oncogene · doi:10.1038/onc.2008.155 · Cited by 84
Coronary heart disease and menopause management: The swinging pendulum of HRT
Stevenson, J. C., Hodis, H. N., Pickar, J. H., & Løbo, R. A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.033 · Cited by 73
Rosenberg, L. U., Granath, F. N., Dickman, P. W., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2145 · Cited by 52
Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Newcomb, P. A., Egan, K. M., Trentham‐Dietz, A., Titus-Ernstoff, L. T., Baron, J. A., Hampton, J. M., Stampfer, M. J., & Willett, W. C. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0610 · Cited by 46
Postmenopausal Hormone Use, Screening, and Breast Cancer: Characterization and Control of a Bias
Joffe, M. M., Byrne, C., & Colditz, G. A. (2001) · Epidemiology · doi:10.1097/00001648-200107000-00013 · Cited by 35
[The role of estrogens in angiogenesis in the female reproductive system].
Dobrzycka, B., Kinalski, M., Piechocka, D. I., & Terlikowski, S. J. (2009) · PubMed · Cited by 10
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Self-citation
Metadata
- Authors
- Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J., Sarto, G. E., Johnson, K. C., Wactawski-Wende, J., Ravdin, P. M., Schenken, R., Hendrix, S. L., Rajkovic, A., Rohan, T. E., Yasmeen, S., Prentice, R. L., & WHI Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-10-20
- Volume
- 304
- Issue
- 15
- Pages
- 1684
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2139272277
- Cited by
- 567
- References
- 36
- FWCI
- 50.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.